HSBC Holdings’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.91M Sell
40,300
-17,400
-30% -$900K ﹤0.01% 1427
2026
Q1
$2.84M Buy
+57,700
New +$2.69M ﹤0.01% 1375
2024
Q2
Sell
-33,600
Closed -$3.58M 3096
2024
Q1
$3.58M Sell
33,600
-23,600
-41% -$2.38M ﹤0.01% 1226
2023
Q4
$5.68M Sell
57,200
-6,800
-11% -$572K ﹤0.01% 1107
2023
Q3
$6.59M Buy
64,000
+26,900
+73% +$3M 0.01% 989
2023
Q2
$4.54M Buy
37,100
+13,500
+57% +$1.8M ﹤0.01% 1092
2023
Q1
$3.59M Hold
23,600
﹤0.01% 1252
2022
Q4
$4.16M Hold
23,600
﹤0.01% 1338
2022
Q3
$2.84M Buy
+23,600
New +$3.58M ﹤0.01% 1405

Other funds holding MRNA

HSBC Holdings's MRNA Position: Q2 2026 in Review

HSBC Holdings increased its Moderna (MRNA) stake by 30% in Q2 2026, buying an estimated $7.56M and bringing the position to 636,199 shares worth $45.2M. The position accounts for 0.02% of the portfolio, ranked #562.

HSBC Holdings first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $141M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • HSBC Holdings held 636,199 shares of Moderna worth $45.2M as of Q2 2026.
  • HSBC Holdings bought 146,111 Moderna shares in Q2 2026, an estimated $7.56M.
  • Moderna made up 0.02% of HSBC Holdings's portfolio in Q2 2026, its #562 holding.
  • HSBC Holdings first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • HSBC Holdings's Moderna position peaked at $141M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.